Literature DB >> 29889293

Comparison of Single-Step Transepithelial Photorefractive Keratectomy With or Without Mitomycin C in Mild to Moderate Myopia.

Soheil Adib-Moghaddam, Saeed Soleyman-Jahi, Ghazale Tefagh, Salar Tofighi, Michael A Grentzelos, George D Kymionis.   

Abstract

PURPOSE: To compare efficacy and safety of single-step transepithelial photorefractive keratectomy (PRK) with or without mitomycin C (MMC) in patients with mild to moderate myopia.
METHODS: Patients with mild to moderate myopia (≤ -5.50 diopters [D]) underwent single-step transepithelial PRK using the Amaris laser (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Total ablation depth (epithelium and stroma) was 160 μm or less. The right eye of each patient was treated with 0.02% MMC for 10 seconds, whereas the left eye did not receive any MMC. Corneal haze, endothelial cell indices, refraction, visual acuity, contrast sensitivity, and higher order aberrations were assessed preoperatively and postoperatively.
RESULTS: In this comparative case series, 71 patients (16 men and 55 women; 142 eyes) were enrolled. Mean patient age was 27.97 ± 5.74 years. Mean preoperative spherical equivalent of patients' right and left eyes were -3.20 ± 1.20 and -3.30 ± 1.20 diopters, respectively (P = .70); other preoperative visual parameters were also comparable. Incidence of 2+ grade of haze was detected in 1 (2.5%) right and 2 (5.0%) left eyes (P > .99) 3 to 6 months postoperatively. Incidence of 1+ degree of haze was also comparable. No eye developed 3+ degrees or more of haze. One year postoperatively, both eyes achieved comparable refraction, visual acuity, contrast sensitivity, and higher order aberrations, and no greater than trace haze was detected. MMC-treated eyes suffered a greater loss of endothelial cell density (P < .001) and showed higher variance in cell size (P = .001).
CONCLUSIONS: Single-step transepithelial PRK with or without MMC showed similar efficacy and incidence of haze in eyes with mild to moderate myopia with total ablation depths of 160 μm or less. However, MMC-treated eyes showed a worse profile of endothelial cell indices. Applications of MMC in this subgroup of patients may be reconsidered. [J Refract Surg. 2018;34(6):400-407.]. Copyright 2018, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29889293     DOI: 10.3928/1081597X-20180402-02

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  4 in total

1.  Plasma Rich in Growth Factors (PRGF) in Transepithelial Photorefractive Keratectomy (TPRK).

Authors:  José-María Sánchez-González; Federico Alonso-Aliste; Davide Borroni; Jonatan Amián-Cordero; Concepción De-Hita-Cantalejo; Raúl Capote-Puente; María-José Bautista-Llamas; María Carmen Sánchez-González; Marina Rodríguez-Calvo-de-Mora; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2021-04-30       Impact factor: 4.241

2.  Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.

Authors:  Ronald M Sanchez-Avila; Edmar E Uribe-Badillo; Javier Fernández-Vega Sanz; Francisco Muruzabal; Nancy Jurado; Belén Alfonso-Bartolozzi; Jose F Alfonso; Begoña Baamonde; Eduardo Anitua; Jesus Merayo-Lloves
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

3.  Effect of Transepithelial Photorefractive Keratectomy without Mitomycin C in the Treatment of Femtosecond Laser In Situ Keratomileusis Corneal Flap Complications.

Authors:  Jing Wang; Weiqian Cao; Liming Tao
Journal:  J Ophthalmol       Date:  2021-01-13       Impact factor: 1.909

4.  Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes.

Authors:  Jean Baptiste Giral; Florian Bloch; Maxime Sot; Yinka Zevering; Arpine El Nar; Jean Charles Vermion; Christophe Goetz; Louis Lhuillier; Jean-Marc Perone
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.